For example, Kadcyla (Trastuzumab emtansine/T-DM1)is effective in the treatment of ERBB2-positive breast cancer, but it has not delivered remarkable clinical benefit in ERBB2-positive gastric cancer [30]. This evidence concerns the gene ERBB2 and breast cancer.